AdAlta Limited (ASX:1AD) is a drug discovery, development and commercialisation company. We are focused on generating a pipeline of next generation therapeutics to treat challenging diseases in fibrosis and oncology.
AdAlta Limited (ASX: 1AD) is an Australian public biotechnology company focused on the development and commercialisation of its i-body technology platform that has generated a pipeline of i-bodies (drugs), with an initial focus on treating fibrotic diseases.
If you wish to receive further information about the company, please contact us.
AdAlta Ltd is happy to provide information about your shareholding.
Your information is held on a share registry, which can be found at https://automic.com.au.
As an investor you can obtain information on shareholdings and transactions by accessing the Automic website. Please contact the Automic Registry Service.
Phone (aus): 1300 288 664
Please contact Dr Tim Oldham on +61 3 9479 5159 with further investment-related questions.
Further information can also be found on the ASX website.